ASTRO 2017: Aggressive Therapy Fails in High-Risk Endometrial Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video reviews results of a phase III trial that compared pelvic radiation therapy vs vaginal cuff brachytherapy plus chemotherapy in patients with early-stage, high-risk endometrial cancer.

In this video, Marcus Randall, MD, of the University of Kentucky College of Medicine, discusses a phase III Gynecologic Oncology Group (GOG) trial that compared pelvic radiation therapy vs vaginal cuff brachytherapy plus paclitaxel/carboplatin in patients with early-stage, high-risk endometrial cancer.

Randall presented results of the study (abstract LBA-1) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Recent Videos
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Related Content
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Andrea I. Nañez, MD;Maria C. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS
December 4th 2025
Article

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Roman Fabbricatore
November 24th 2025
Article

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer

Tim Cortese
November 21st 2025
Article

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Real-World Niraparib Efficacy Similar to Phase 3 Data in Ovarian Cancer

Tim Cortese
November 18th 2025
Article

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.